MSD and Glenmark appeal pay-for-delay Zetia dispute
Pharmaceutical companies MSD and Glenmark have argued that the class certification of wholesale buyers of cholesterol drug Zetia should be reversed because the circumstances of the class members do not justify an award of class status.
India approves COVID-19 vaccines ahead of huge rollout
India has granted emergency approval to COVID-19 vaccines developed by AstraZeneca and Oxford University and one from the state-run institute Bharat Biotech, ahead of a huge immunisation drive that is planned to begin this week.
Teva fails to reclassify MS drug to thwart generics
Teva Pharmaceuticals has failed to redefine its multiple sclerosis drug Copaxone as a biological product instead of a drug, after the US District Court for the District of Columbia dismissed its efforts as “uncompetitive” on December 31.
Apollo’s Covis sues over preterm-birth drug patents
Aurobindo’s subsidiary Eugia allegedly infringed two patents for an injectable treatment for reducing the risk of premature birth, according to a lawsuit by Covis Pharma, a Luxembourg-based unit of Apollo Global Management.
Skinny-label ruling will ‘decimate’ Hatch-Waxman, Fed Circuit told
One of the architects of the Hatch-Waxman Act has urged judges to reverse a decision which he says nullifies a key provision of the generic drug legislation.
Canopy sues GW Pharma over cannabis patent
Canadian medical cannabis company Canopy Growth has accused GW Pharma of using a patented technological process to produce its flagship epilepsy treatment, Epidiolex, without authorisation.
Medline accuses competitor of confusing customers over COVID-19 PPE
A manufacturer of healthcare products including personal protective equipment has accused a newly incorporated company of trying to confuse consumers during the Covid-19 pandemic.
Ex-DuPont employee gets 42 months over trade secret theft
A US federal appeals court has upheld a 42-month prison sentence for an ex-employee of DuPont Industrial Biosciences who stole trade secrets from the firm.
Ravgen and Myriad in patent dispute over DNA testing tech
Biotechnology company Ravgen has accused Myriad Genetics and Myriad Women’s Health of infringing two patents covering non-invasive DNA testing technology.
Fed Circuit refuses to revive Biogen’s MS drug dispute
Biogen has lost its long-standing fight to recover billions of dollars in royalties from the sale of a multiple sclerosis (MS) drug, after the US Court of Appeals for the Federal Circuit rejected Biogen’s request that it reconsider its own ruling.
